1361 related articles for article (PubMed ID: 3091760)
1. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
2. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Lange KW
Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
[TBL] [Abstract][Full Text] [Related]
3. Neuropharmacological manipulations with MPTP.
Barnes NJ; Bradbury AJ; Costall B; Domeney AM; Kelly ME; Naylor RJ
J Neural Transm Suppl; 1986; 20():47-63. PubMed ID: 3091761
[TBL] [Abstract][Full Text] [Related]
4. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway.
Bradbury AJ; Costall B; Domeney AM; Jenner P; Kelly ME; Marsden CD; Naylor RJ
Nature; 1986 Jan 2-8; 319(6048):56-7. PubMed ID: 3484542
[TBL] [Abstract][Full Text] [Related]
5. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
6. MPTP: a pharmacological tool to study parkinsonism.
Kulkarni SK; Mehta AK; Aley KO; Shukla VK
Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
[TBL] [Abstract][Full Text] [Related]
7. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
[TBL] [Abstract][Full Text] [Related]
8. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
9. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
Zuddas A; Fascetti F; Corsini GU; Piccardi MP
Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
[TBL] [Abstract][Full Text] [Related]
10. Selegiline and the prophylaxis of Parkinson's disease.
Sandler M; Willoughby J; Glover V; Gibb C
J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
[TBL] [Abstract][Full Text] [Related]
11. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
[TBL] [Abstract][Full Text] [Related]
12. The role of MAO in MPTP toxicity--a review.
Glover V; Gibb C; Sandler M
J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
[TBL] [Abstract][Full Text] [Related]
13. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
14. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
[TBL] [Abstract][Full Text] [Related]
15. [Medicamentous strategy for improving the quality of life in the senescence].
Knoll J
Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
[TBL] [Abstract][Full Text] [Related]
16. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
18. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM
J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293
[TBL] [Abstract][Full Text] [Related]
19. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
Matsubara K
Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
[TBL] [Abstract][Full Text] [Related]
20. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
